Viatris Newsroom

Viatris Is Maintained at Underweight by Barclays

Dow JonesNov 9 03:29

Viatris Analyst Ratings

BenzingaNov 9 03:19

Barclays Maintains Viatris(VTRS.US) With Sell Rating, Raises Target Price to $12

Futu NewsNov 8 19:31

Barclays Maintains Viatris(VTRS.US) With Sell Rating, Maintains Target Price $11

Futu NewsNov 6 16:33

Barclays Maintains Viatris(VTRS.US) With Sell Rating, Maintains Target Price $11

Futu NewsOct 28 17:34

Jefferies Maintains Viatris(VTRS.US) With Buy Rating, Maintains Target Price $15

Futu NewsOct 15 20:31

Piper Sandler Maintains Viatris(VTRS.US) With Hold Rating, Maintains Target Price $13

Futu NewsSep 27 08:31

Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma

Seeking AlphaSep 6 20:42

Piper Sandler Maintains Viatris(VTRS.US) With Hold Rating, Maintains Target Price $13

Futu NewsJul 24 19:31

Viatris Analyst Ratings

BenzingaJul 19 20:50

Jefferies Reinstates Buy on Viatris, Announces $15 Price Target

BenzingaJul 19 20:49

UBS Trims Viatris Price Target to $12 From $13, Maintains Neutral Rating

MT NewswiresMay 10 23:16

Viatris Analyst Ratings

BenzingaMar 29 00:25

Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $11

BenzingaNov 23, 2023 01:57

Viatris Analyst Ratings

BenzingaNov 23, 2023 01:52

B of A Securities Downgrades Viatris to Underperform, Announces $9 Price Target

BenzingaOct 23, 2023 19:21

Viatris Analyst Ratings

BenzingaOct 23, 2023 19:20

Piper Sandler Sticks to Their Hold Rating for Viatris (VTRS)

TipRanksAug 8, 2023 20:55

Barclays Downgrades Viatris to Underweight, Announces $11 Price Target

BenzingaJun 23, 2023 17:47

Barclays Downgrades Viatris to Equal-Weight, Lowers Price Target to $11

BenzingaApr 25, 2023 21:06